In order to investigate the clinical relevance of ZEB1‐mediated EMT in response to docetaxel therapy, we performed IHC analysis of ZEB1 tumour expression in 27 patients with prostate cancer; 14 of whom were treated with docetaxel prior to radical prostatectomy. The gene discussed is ZEB1; the disease is prostate carcinoma.